NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

November 2, 2025

Study Completion Date

November 2, 2025

Conditions

Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Kaposi SarcomaAdvanced Lung Non-Small Cell CarcinomaAdvanced Lung Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAdvanced MelanomaAdvanced Ovarian CarcinomaAdvanced Prostate CarcinomaAdvanced Renal Cell CarcinomaAdvanced Thyroid Gland Medullary CarcinomaAdvanced Triple-Negative Breast CarcinomaAdvanced Urothelial CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8HIV InfectionMetastatic Differentiated Thyroid Gland CarcinomaMetastatic Head and Neck CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Kaposi SarcomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Ovarian CarcinomaMetastatic Prostate CarcinomaMetastatic Renal Cell CarcinomaMetastatic Thyroid Gland Medullary CarcinomaMetastatic Triple-Negative Breast CarcinomaMetastatic Urothelial CarcinomaRecurrent Differentiated Thyroid Gland CarcinomaRecurrent Head and Neck CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Kaposi SarcomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaRecurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaRecurrent Thyroid Gland Medullary CarcinomaRecurrent Triple-Negative Breast CarcinomaRecurrent Urothelial CarcinomaRefractory Differentiated Thyroid Gland CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage III Lung Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Thyroid Gland Medullary Carcinoma AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cabozantinib S-malate

Given PO

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (3)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

60611

Northwestern University, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH